1.Oral sirolimus in the treatment of adult eruptive cherry angiomas
Christine Lyka R. Sayson, MD ; Aira Monica R. Abella, MD ; Danielle Marlo R. Senador, MD ; Leilani R. Senador, MD, FPDS ; Gisella U. Adasa, MD, FPDS
Journal of the Philippine Dermatological Society 2023;32(1):35-38
Introduction:
Cherry angiomas are a common type of acquired vascular proliferation of the skin which manifest as single or multiple
bright red spots that usually appear on the trunk and arms. They are generally asymptomatic; patients may opt to remove the lesions for
cosmetic reasons and prevention of bleeding. Conventionally, most cherry angiomas are treated with curettage, laser, and electrosurgery. Herein, we report a case of multiple cherry angiomas managed alternatively with oral sirolimus.
Case:
A 47-year-old Filipino female presented with a 10-month history of gradually enlarging multiple bright-red papules and
pedunculated nodules with a propensity to spontaneously bleed on gentle manipulation involving the scalp and forehead. Clinicopathological correlation suggests a diagnosis of eruptive cherry angiomas. The patient was started on oral sirolimus, a mammalian target of
rapamycin (mTOR) inhibitor.
Conclusion
We present a case of a patient with eruptive cherry angiomas who experienced significant decrease in size and bleeding
with treatment of oral sirolimus with minimal adverse effects. For patients with eruptive cherry angiomas, especially with contraindicated
comorbidities, first-line therapeutic option treatments with oral sirolimus can be beneficial.
sirolimus
;
vascular malformation
2.A case of green nail syndrome secondary to P. aeruginosa and C. parapsilosis treated with topical nadifloxacin and oral fluconazole in a 31-year-old Filipino female
Angeli Elaine A. Pangilinan, MD ; Nicole R. Rivera, MD ; Leilani R. Senador, MD, FPDS
Journal of the Philippine Dermatological Society 2023;32(1):27-30
Introduction:
Pseudomonas aeruginosa is an opportunistic, gram-negative bacillus that can contaminate skin or open wounds to
cause skin infections that are historically difficult to manage. The pathogenesis of green nail syndrome (GNS) begins with hyperhydration (occlusion, sweating, maceration) or destruction (microtrauma, dermatitis) of the epidermis thus disrupting the physical barrier,
leading to the colonization and proliferation of P. aeruginosa. This case explores the off-label use of nadifloxacin, a fluoroquinolone approved for acne and bacterial skin infections in some countries, to treat a case of GNS.
Case Report:
This is a case of a 31-year-old Filipino female who presented with a four-month history of green discoloration of the lateral
portion of the right thumbnail with a medical history of antiphospholipid antibody syndrome and rheumatoid arthritis. Clinical examination showed a dystrophic thumbnail with greenish discoloration, erythema and swelling around the base of the cuticle, and distal
onycholysis. Laboratory findings revealed co-infection of P. aeruginosa and Candida parapsilosis. The patient was effectively treated with
topical nadifloxacin and oral fluconazole.
Conclusion
This case highlights the possibility of fungal and polymicrobial infections in GNS and suggests a novel, easy-to-use, and
cost-effective alternative treatment to GNS secondary to P. aeruginosa in the form of topical nadifloxacin.
Candida parapsilosis
;
Pseudomonas aeruginosa
;
Onychomycosis
3.Treatment conundrum: A case of recalcitrant Epidermolysis Bullosa Acquisita (EBA) in a 50-year-old Filipino male
Danelle Anne L. Santos, MD ; Aira Monica R. Abella, MD ; Danica-Grace Tungol, MD, DPDS ; Leilani R. Senador, MD, FPDS
Journal of the Philippine Dermatological Society 2023;32(1):31-34
Introduction:
Epidermolysis Bullosa Acquisita (EBA) is a rare autoimmune blistering disease which presents in the skin and mucous
membranes. The decrease in anchoring fibrils in the basement membrane zone causes separation of the epidermis from the dermis,
resulting in its blistering presentation. The treatment plan will depend on the severity of the disease. The first-line treatment for mild
EBA includes topical corticosteroids and immunomodulators such as dapsone and colchicine; while severe cases of EBA may be given
intravenous immunoglobulins, systemic steroids, and immunosuppressants such as azathioprine and cyclophosphamide.
Case Report:
This is a case of a 50-year-old Filipino male who presented with a 2-year history of vesicles and tense bullae which evolved
into papules, plaques and erosions with scarring and milia formation on the scalp and trauma-prone areas of the trunk and extremities.
Clinical examination revealed multiple, well-defined, irregularly shaped erythematous papules and plaques with crusts, scales, erosions, pearl-like milia and scarring on the chest, back, upper, and lower extremities. The oral mucosa was moist with some ulcers on the
tongue. Histopathologic examination using Hematoxylin and Eosin (H&E) stain revealed the absence of the epidermis with retention of
dermal papillae suggestive of subepidermal clefting. Further examination with direct immunofluorescence (DIF) revealed monoclonal
immunoglobulin (IgG) deposits demonstrating an intense linear fluorescent band at the dermoepidermal junction, consistent with Epidermolysis Bullosa Acquisita. Overall, the combined administration of prednisone, azathioprine, and colchicine resulted only in transient
and incomplete resolution of lesions in this case of EBA.
Conclusion
The management of EBA is mostly supportive with the goal of minimizing complications. Combination treatments using
steroids, colchicine, and azathioprine have been reported with various results. Its management remains challenging as most cases are
refractory to treatment.
Epidermolysis Bullosa Acquisita
;
bullous disease
;
azathioprine
;
colchicine
;
prednisone